Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
Cipla
Citi
Boehringer Ingelheim
Teva

Generated: August 24, 2019

DrugPatentWatch Database Preview

TESAMORELIN ACETATE - Generic Drug Details

  Try a free trial


See Plans and Pricing

« Back to Dashboard

What are the generic sources for tesamorelin acetate and what is the scope of tesamorelin acetate patent protection?

Tesamorelin acetate is the generic ingredient in one branded drug marketed by Theratechnologies and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tesamorelin acetate has forty-four patent family members in sixteen countries.

One supplier is listed for this compound.

Summary for TESAMORELIN ACETATE
International Patents:44
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 1
DailyMed Link:TESAMORELIN ACETATE at DailyMed
Synonyms for TESAMORELIN ACETATE
(3E)-Hex-3-enoylsomatoliberin (human) acetate (salt)
901758-09-6
LGW5H38VE3
Tesamorelin acetate [USAN]
TH9507
UNII-LGW5H38VE3

US Patents and Regulatory Information for TESAMORELIN ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for TESAMORELIN ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 ➤ Sign Up ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 ➤ Sign Up ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Covington
UBS
US Department of Justice
Queensland Health
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.